- Tango will receive $50 million up front
- The company could receive up to $1.7 billion in additional payments
- The partnership will focus on building a pipeline of novel immuno... read more
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced... read more
Janssen Pharmaceutical today unveiled 96-week results from the pivotal Phase 3 AMBER study of Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide... read more
BPU Holdings... read more
... read more
Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing of a €79 million series... read more
TP Therapeutics announced on 10/24/18 a global collaboration agreement to develop and commercialize a next-generation sequencing (NGS) companion diagnostic (CDx) for repotrectinib, TP... read more
Bain Capital, LP and... read more
Copyright © 2019,